Introduction and Phrmacology

Cabergoline (brand names Dostinex® and Cabaser®), an ergot-derivative, is a potent dopamine receptor agonist on D2-Receptors. It also acts on dopamine-receptors in lactophilic hypothalamus cells and causes thereby a suppression of the prolactin-production in pituitary gland. Species About 50, including: Claviceps africanum Claviceps fusiformis Claviceps paspali Claviceps purpurea Ergot is the common name of a fungus in the genus Claviceps. ...

Pharmacokinetics

Following an oral single dose the drug is resorbed within 0.5 to 4 hours from the GI-Tract with considerable interindividual differences. Meals do not alter the absorption characteristic. Human bioavailibility was not determined, because the drug is intended for oral use only. In mice and rats the absolute bioavailability was 30 and 63%, respectively. Cabergoline is rapidly and to a great extend metabolized in the liver and excreted in bile and far less in urine. All metabolites are less active than the parental drug or inactive. The human elimination halflife is estimated to be 63 to 68 hours in patients with M. Parkinson and 79 to 115 hours in patients with pituitary tumors.

Carcinogenity

In rodents a dose dependent increase in malignant tumors has been found. They are thought to be species-specific. No clinical data exists on carcinogenity in humans.

Uses

• Monotherapy of Morbus Parkinson in the early phase.
• Combination therapy of Morbus Parkinson in the progressive phase together with levodopa and a decarboxylase-inhibitor like carbidopa.
• Adjunctive therapy of prolactin-producing tumors of the pituitary gland (microprolactinomes).
• In some countries also : ablactation and dysfunctions associated with hyperprolactinemia (amenorrhea, oligomenorrhea, anovulation, und galactorrhea).

Amenorrhoea (BE) or amenorrhea (AmE) is the absence of a menstrual period in a woman of reproductive age. ... Oligomenorrhea is the medical term for infrequent or light menstrual periods in women of child-bearing age. ... In medicine, anovulation is absence of ovulation when it would be normally expected (in a post-menarchal, premenopausal woman). ...

Off-Label/Recreational Uses

It has at times been used as an adjunct to SSRI antidepressants as there is some evidence that it counteracts certain side effects of those drugs such as reduced libido and anorgasmia. It also has been suggested online that it has a possible recreational use in reducing or eliminating the male refractory period. SSRI is an acronym that stands for several things: It is a class of antidepressants called selective serotonin reuptake inhibitor SSRI also is used as the stock symbol for Silver Standard Resources Inc. ... An antidepressant is a medication used primarily in the treatment of clinical depression. ... A refractory period, in physiology, is a period of time during which an organ or cell is incapable of performing a particular action. ...

Contraindications and Precautions

• Hypersensitivity to ergot-derivatives
• Pediatric Patients (no clinical experience)
• Severely impaired liver function or cholestasis
• Comedication with drugs metabolized mainly by CYP P450 such as erythromycin and ketoconazole, because increased plasma levels of cabergoline may result.
• Cautions : severe cardiovascular disease, Raynaud's Syndrome, gastroduodenal ulcus, active gastrointestinal bleeding, hypotension.

it relates to ciongetive pressures on the intestinal walls from blockage related to low fiber in the diet. ... Erythromycin is a macrolide antibiotic which has an antimicrobial spectrum similar to or slightly wider than that of penicillin, and is often used for people who have an allergy to penicillins. ... Ketoconazole is a synthetic antifungal drug used to prevent and treat skin and fungal infections, especially in immunocompromised patients such as those with AIDS. Due to its side-effect profile, it has been superseded by newer antifungals, such as fluconazole and itraconazole. ...

Pregnancy and Lactation

• Pregnancy : Approximately 100 female patients became pregnant under therapy with cabergoline for hyperprolactinemic conditions. The incidence of spontanous aborts and congenital abnormalities was comparable to nontreated patients. Nonetheless womem, wishing to become pregnant, should wait a safety period of 4 weeks after discontinuation of cabergoline. Patients becoming pregant under therapy should terminate cabergoline immediately, if possible.
• Lactation : In rats cabergoline was found in the maternal milk. Since it is not known, if this effect is also seen in humans, lactating women should not be treated.

Side Effects

Approximately 200 patients with newly diagnostizised M. Parkinson participated in a clinical study regarding the monotherapy with cabergoline. Seventynine (79) % reported at least one side effect. These side effects were chiefly mild or moderate:

• GI-Tract: Side effects were extremly frequent. Fiftythree Per Cent of patients reported side effects. Nausea (30%), obstipation (22%), and dry mouth (10%) were very frequent. Frequent were gastric irritation (7%), vomiting (5%), and dyspepsia (2%).
• Psychiatric Disturbances and CNS : Altogether 51% of patients were affected. Very frequent were disturbances of sleep (somnolence 18%, insomnia 11%), vertigo (27%), and depression (13%). Frequent were dyskinesia (4%) and hallucinations (4%).
• Cardiovascular : Approximately 30% of patients experienced side effects. Most frequent were hypotension (10%), peripheral edema (14%) and non-specific edema (2%). Arrhythmias were encountered in 4.8%, palpitations in 4.3%, and angina pectoris in 1.4%.

In a combinatiion study with 2,000 patients also treated with levodopa the incidence and severity of side effects was comparable to monotherapy. Encountered side effects required a termination of cabergoline treatment in 15% of patients. Additional side effects were infrequent cases of hematological side effects, and an occasional increase in liver enzymes or serum creatinine without signs or symptoms.

As with other ergot-derivatives pleuritis, exsudative pleura disease, pleura fibrosis, lung fibrosis, and pericarditis are seen. These side effects are noted in less than 2% of patients. They require immediate termination of treatment. Clinical improvement and normalization of X-Ray findings are normally seen soon after cabergoline withdrawal.

The reported incidence and severity of side effects in hyperprolactinemic patients was comparable.

Interactions

No interactions were noted with levodopa or seligiline. The drug should not be combined with other ergot-derivatives. Dopamine Antagonists such as antipsychotics and metoclopramide inhibit the clinical action of cabergoline and should therefore not be used concomitantly. The use of antihypertensive drugs should be intensively monitored because excessive hypotension may result from the combination. Metoclopramide is a parasympathomimetic, and is also a potent dopamine antagonist that enters the central nervous system. ...

Dosage

• Morbus Parkinson : monotherapy : The therapy should be started with 0.5mg daily. The usual maintenance dose is 2 to 4mg daily. In combination therapy usually 2 to 6mg daily are needed.
• Tuumors of the pituitary gland and other hyperprolactinemic conditions: Initially 0.5mg per week(!), slowly increasing to 4.5mg per week, if necessary.
• Ablactation : According to specific treatment scheme.

External links

• Cabergoline (Systemic) - Medlineplus.org
• Dostinex - rxlist.com
• Scientifc Information on Dostinex and Cabaser (Swiss, in German)